As the prevalence of obesity, type 2 diabetes, and the opioid crisis in the United States continues to rise, so does chronic liver disease. From hepatitis C and hepatitis B to non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), liver disease affects a significant portion of the U.S. population. Hepatitis C virus (HCV) is a leading cause of cirrhosis, liver cancer, and mortality worldwide. Injection drug use, arising in conjunction with the opioid crisis, has contributed significantly to the increase in HCV infections. Chronic hepatitis B virus (HBV) remains a global epidemic, resulting in significantly increased morbidity and mortality. Furthermore, the rising number of obese and diabetic patients has resulted in the increased prevalence of NAFLD, which may progress to NASH in a large number of patients. To help clinicians and patients navigate the changing landscape of liver disease, we designed the Liver Disease Hub to provide resources and guidelines for screening, testing, and treatment of liver disease.
Our activities offer many credit types, including CME, AAFP Prescribed Credit, CNE, CPE, ABIM MOC, and ABP MOC. Each activity has been designed to meet the requirements for CME for MIPS. See each activity’s information page for the exact credit type and amount of credit offered.
Live Q&A: At-Risk Patients Hidden in Plain Sight: Real-World Strategies for Screening and Treating Hepatitis B Virus
[themo_button text=”Register Now” url=”https://www.cmeoutfitters.com/transfers/cm/?ID=43697″ type=”standard” target=”_blank”] |
Wednesday, September 23, 2020 | 6:30 PM – 7:00 PM ET Join this live Q&A session to ask our expert faculty your questions based on the CME Outfitters virtual symposium where expert faculty utilized augmented reality to add visualization to their discussion of how to implement routine screening protocols for HBV in primary care settings, how to optimize the efficacy and safety profiles of current agents, and the importance of providing culturally appropriate counseling and support services to patients. To view the full activity ahead of this live Q&A, click here. |
Streamlining the Journey to a Cure: Optimizing the Hepatitis C Virus Care Cascade
[themo_button text=”Participate Now” url=”https://www.cmeoutfitters.com/transfers/cm/?ID=40667″ type=”standard” target=”_blank”] |
Recent studies have shown persistent gaps in the HCV care continuum, with underdiagnosis and undertreatment being the major barriers toward achieving the goal of eliminating HCV. With primary care clinicians and community health workers representing an important front-line resource for early screening and treatment for HCV infection, it is imperative to educate primary care providers (PCPs) and community health workers to expand the HCV workforce and linkage-to-care opportunities. This CME Outfitters on-demand webcast features expert faculty hosting an interactive discussion on implementing HCV screening, developing new methods of coordinated care, and addressing barriers to treatment access. |
At-Risk Patients Hidden in Plain Sight: Real-World Strategies for Screening and Treating Hepatitis B Virus
[themo_button text=”Participate Now” url=”https://www.cmeoutfitters.com/transfers/cm/?ID=39668″ type=”standard” target=”_blank”] |
In this CME Outfitters virtual symposium, expert faculty utilized augmented reality to add visualization to their discussion of how to implement routine screening protocols for HBV in primary care settings, how to optimize the efficacy and safety profiles of current |
A Deeper Dive into NASH Diagnosis and Treatment: An Augmented Reality Experience
[themo_button text=”Participate Now” url=”https://www.cmeoutfitters.com/transfers/cm/?ID=39667″ type=”standard” target=”_blank”] |
With the majority of high-risk patients first seen in the primary care setting, it is imperative that internists and primary care physicians (PCPs) identify patients at risk for NASH. Although liver biopsy was previously the best test for identifying the critical endpoints of NASH, several noninvasive, yet effective, tests have been developed recently that have the potential to be implemented in primary care settings. In this CME Outfitters webcast, expert faculty utilized Augmented Reality (AR) to visually dive into NASH, with particular focus on risk stratification, diagnosis, and emerging targeted therapies. |
A Grassroots Approach to Weed Out HIV and HCV in Special OUD Populations
[themo_button text=”Participate Now” url=”https://www.cmeoutfitters.com/transfers/cm/?ID=31539″ type=”standard” target=”_blank”] |
In this CME Outfitters on-demand webcast, expert faculty discuss strategies for HIV and HCV testing in special OUD populations, applying evidence-based treatment approaches, as well as prevention strategies, including PrEP, for patients with OUD at high risk for HIV infection. |
What the Future Holds for NASH: An Augmented Reality Look into Disease Stating and Targeted Therapies
[themo_button text=”Participate Now” url=”https://www.cmeoutfitters.com/transfers/cm/?ID=35601″ type=”standard” target=”_blank”] |
Given the rising prevalence of non-alcoholic fatty liver disease (NAFLD) and the societal and economic burden of its aggressive subtype, non-alcoholic steatohepatitis (NASH), it is important that hepatologists and gastroenterologists are equipped with the latest tools to diagnose NASH. This CME Outfitters OnDemand features expert faculty integrating augmented reality (AR) to discuss pathways, therapeutic targets, and disease progression providing the learners with the best visual experience to enable them to integrate the latest tools for diagnosis and management of patients with NASH. |
HCV
HIV-HCV Coinfection
HCV